Infectious Diseases News and Research

RSS

PolyMedix secures $14M credit facility with Hercules Technology II

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has secured a $14 million credit facility with Hercules Technology II, L.P., an affiliate of Hercules Technology Growth Capital, Inc.

1 Apr 2010

Soligenix's revenues for 2009 increase by 22%

Soligenix, Inc., a late-stage biopharmaceutical company, today announced its financial results for 2009.

1 Apr 2010

VA may expand list of Gulf War illnesses

The Army Times/Veterans Today: "In a boost for veterans of the 1991 Persian Gulf War and those who have served in recent years in Iraq and Afghanistan, the Veterans Affairs Department has proposed changes to its list of illnesses that are presumed connected to service to include nine infectious diseases."

1 Apr 2010

GSK, Isis Pharmaceuticals collaborate to develop new therapeutics for rare and serious disease

GlaxoSmithKline and Isis Pharmaceuticals, Inc. announced today a new strategic alliance that will apply the Isis antisense drug discovery platform to seek out and develop new therapeutics against targets for rare and serious disease, including infectious diseases and some conditions causing blindness.

31 Mar 2010

PhRMA report: 234 medicines in development for special health care needs of children

America's pharmaceutical research and biotechnology companies are developing 234 medicines for the special health care needs of children, according to a new report released today by the Pharmaceutical Research and Manufacturers of America.

31 Mar 2010

PolyMedix completes Phase 1B clinical study with PMX-30063 defensin-mimetic antibiotic

PolyMedix, Inc., an emerging bio-technology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B clinical study with its novel defensin-mimetic antibiotic, PMX-30063. The data from the study demonstrate that administration of multiple doses of PMX-30063 are safe and well-tolerated at dose levels which showed bactericidal activity in blood samples drawn from subjects in the study.

31 Mar 2010

NovaBay Pharmaceuticals reports net income of $2.7M for 2009 against year-ago loss

NovaBay Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported full-year and fourth quarter financial results for 2009. The company also highlighted recent progress of its proprietary and partnered development programs.

30 Mar 2010

Emory Institute of Drug Discovery and Zirus collaborate to develop new anti-viral drugs

The Emory Institute of Drug Discovery and Zirus, Inc., a biotechnology company based in Buford, Georgia, have entered into a collaboration and research agreement to develop novel compounds to treat infectious disease. Zirus uses a proprietary method for identifying genes and gene products in host cells that, when blocked, can prevent viruses from multiplying. Over the past several years, either alone or in collaboration with partners, including the Centers for Disease Control and Prevention (CDC), Zirus has identified, licensed and filed patents on more than 1000 targets.

30 Mar 2010

Wall Street journal examines fundraising efforts by GAVI, Global Fund

The GAVI Alliance and the Global Fund to Fight AIDS, Tuberculosis and Malaria "on Friday began an effort to raise as much as $24 billion from members of the Group of 20 nations that will test whether a major push begun a decade ago against infectious diseases can survive the global recession," the Wall Street Journal reports. The two groups held meetings last week in The Hague with government representatives from existing and potential donor nations, according to the newspaper.

30 Mar 2010

Preclinical study of DAS181 for treatment and prevention of ILI published

NexBio, Inc. announced today the publication in the Journal of Infectious Diseases of a preclinical study suggesting that treatment with DAS181 (Fludase®) may reduce the risk of secondary bacterial pneumonia following influenza virus infection.

30 Mar 2010

Research challenges current thinking about TB bacterium

Two new tuberculosis studies by UT Southwestern Medical Center researchers provide good news and bad news about the bacterium that infects nearly a third of the world's population and a disease that kills nearly 2 million people each year.

30 Mar 2010

DIATHERIX GI test panel can detect nine types of GI infections

DIATHERIX Laboratories adds a gastrointestinal panel to its lineup of highly sensitive, rapid response diagnostic tests. In a single result, the DIATHERIX GI panel can detect and differentiate nine types of GI infections so physicians can quickly identify patients who have severe, life-threatening infections.

30 Mar 2010

Final results from Novavax' Phase II clinical trial of trivalent seasonal influenza VLP vaccine announced

Novavax, Inc. a clinical-stage vaccine company, released the final results from a Phase II clinical trial evaluating Novavax's trivalent seasonal influenza Virus-like particle (VLP) vaccine candidate in healthy adults. The study enrolled healthy volunteers 18 to 49 years in age who were immunized with a single injection of Novavax's trivalent seasonal influenza VLP vaccine matched to the influenza strains recommended for the 2008-2009 influenza vaccine.

29 Mar 2010

Inovio Biomedical's total revenue increased to $2.6M for quarter ended December 31, 2009

Inovio Biomedical Corporation today reported financial results for the quarter and year ended December 31, 2009.

29 Mar 2010

Glue ear: Bacterial nasal spray may help children

Many children have long-term problems with fluid in the middle ear, and sometimes surgery is the only way to shift it. However, a bacterial nasal spray can have the same effect in some children, reveals a thesis from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

29 Mar 2010

Role Tregs play in therapeutic HIV vaccines

Like a skittish driver slamming the brakes, a special class of T cells may be limiting the effectiveness of therapeutic vaccines for HIV by slowing the immune system response too soon, report University of Pittsburgh health science researchers in the current issue of PLoS ONE. Their study, the first to look at the role of regulatory T cells in therapeutic HIV vaccines, may help researchers improve the efficacy of such vaccines by devising methods to circumvent the braking mechanism of these cells.

27 Mar 2010

Antiviral treatment may lead to drug-resistant H1N1 virus: NIAID

Two people with compromised immune systems who became ill with 2009 H1N1 influenza developed drug-resistant strains of virus after less than two weeks on therapy, report doctors from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

27 Mar 2010

New ways to halt the rise of antimicrobial-resistant infections

Preventing, controlling and treating drug-resistant infections is one of the major challenges in modern medicine. Antimicrobial Resistance goes beyond simple definitions and microbiological data to fully explore this rapidly changing area, describing evidence for effective interventions, costs, treatment strategies and directions for future research.

27 Mar 2010

NIH awards $15M grant to UMDNJ-New Jersey Medical School

For the second time in less than one month, the University of Medicine and Dentistry of New Jersey-New Jersey Medical School has been awarded a coveted $15 million grant by the National Institutes of Health.

27 Mar 2010

CA-MRSA becoming common among children admitted to PICU's

Once considered a hospital anomaly, community-acquired infections with drug-resistant strains of the bacterium Staphylococcus aureus now turn up regularly among children hospitalized in the intensive-care unit, according to research from the Johns Hopkins Children's Center.

26 Mar 2010